![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NeuroSearch A/S, Ballerup, Denmark (R.S.H., T.G.D., J.D., S.-P.O., M.G.); Danish Arrhythmia Research Centre and Department of Medical Physiology, Panum Institute, University of Copenhagen, Copenhagen, Denmark (R.S.H., T.G.D., S.-P.O., M.G.); and Department of Pharmacology and Toxicology, Medical Faculty, Dresden University of Technology, Dresden, Germany (T.C., U.R.)
The cardiac action potential is generated by a concerted action of different ion channels and transporters. Dysfunction of any of these membrane proteins can give rise to cardiac arrhythmias, which is particularly true for the repolarizing potassium channels. We suggest that an increased repolarization current could be a new antiarrhythmic principle, because it possibly would attenuate afterdepolarizations, ischemic leak currents, and re-entry phenomena. Repolarization of the cardiac myocytes is crucially dependent on the late rapid delayed rectifier current (IKr) conducted by ether-a-go-go-related gene (ERG) potassium channels. We have developed the diphenylurea compound 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and tested whether this small organic molecule could increase the activity of human ERG (HERG) channels expressed heterologously. In Xenopus laevis oocytes, NS1643 increased both steady-state and tail current at all voltages tested. The EC50 value for HERG channel activation was 10.5 µM. These results were reproduced on HERG channels expressed in mammalian human embryonic kidney 293 cells. In guinea pig cardiomyocytes, studied by patch clamp, application of 10 µM NS1643 activated IKr and significantly decreased the action potential duration to 65% of the control values. The effect could be reverted by application of the specific HERG channel inhibitor 4'-[[1-[2-(6-methyl-2-pyridyl)ethyl]-4-piperidinyl]carbonyl]-methanesulfonanilide (E-4031) at 100 nM. Application of NS1643 also resulted in a prolonged postrepolarization refractory time. Finally, cardiomyocytes exposed to NS1643 resisted reactivation by small depolarizing currents mimicking early afterdepolarizations. In conclusion, HERG channel activation by small molecules such as NS1643 increases the repolarization reserve and presents an interesting new antiarrhythmic approach.
Address correspondence to: Dr. Morten Grunnet, NeuroSearch A/S, Pederstrupvej 93, 2750 Ballerup, Denmark. E-mail: mgr{at}neurosearch.dk
This article has been cited by other articles:
|
|
 |
|
  S.-N. Wu, H. Peng, B.-S. Chen, Y.-J. Wang, P.-Y. Wu, and M.-W. Lin Potent Activation of Large-Conductance Ca2+-Activated K+ Channels by the Diphenylurea 1,3-Bis-[2-hydroxy-5-(trifluoromethyl)phenyl]urea (NS1643) in Pituitary Tumor (GH3) Cells Mol. Pharmacol., December 1, 2008; 74(6): 1696 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Diness, Y.-H. Yeh, X. Y. Qi, D. Chartier, Y. Tsuji, R. S. Hansen, S.-P. Olesen, M. Grunnet, and S. Nattel Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome Cardiovasc Res, July 1, 2008; 79(1): 61 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Xu, M. Recanatini, M. Roberti, and G.-N. Tseng Probing the Binding Sites and Mechanisms of Action of Two Human Ether-a-go-go-Related Gene Channel Activators, 1,3-bis-(2-Hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243) Mol. Pharmacol., June 1, 2008; 73(6): 1709 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fernandez, J. Sargent, F. B. Sachse, and M. C. Sanguinetti Structural Basis for Ether-a-go-go-Related Gene K+ Channel Subtype-Dependent Activation by Niflumic Acid Mol. Pharmacol., April 1, 2008; 73(4): 1159 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gordon, I. M. Lozinskaya, Z. Lin, S. F. Semus, F. E. Blaney, R. N. Willette, and X. Xu 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic Acid (PD-307243) Causes Instantaneous Current through Human Ether-a-go-go-Related Gene Potassium Channels Mol. Pharmacol., March 1, 2008; 73(3): 639 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mewe, I. Wulfsen, A. M. E. Schuster, R. Middendorff, G. Glassmeier, J. R. Schwarz, and C. K. Bauer Erg K+ channels modulate contractile activity in the bovine epididymal duct Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R895 - R904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Bentzen, A. Nardi, K. Calloe, L. S. Madsen, S.-P. Olesen, and M. Grunnet The Small Molecule NS11021 Is a Potent and Specific Activator of Ca2+-Activated Big-Conductance K+ Channels Mol. Pharmacol., October 1, 2007; 72(4): 1033 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Hansen, S.-P. Olesen, and M. Grunnet Pharmacological Activation of Rapid Delayed Rectifier Potassium Current Suppresses Bradycardia-Induced Triggered Activity in the Isolated Guinea Pig Heart J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 996 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zeng, I. M. Lozinskaya, Z. Lin, R. N. Willette, D. P. Brooks, and X. Xu Mallotoxin Is a Novel Human Ether-a-go-go-Related Gene (hERG) Potassium Channel Activator J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 957 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Hansen, T. G. Diness, T. Christ, E. Wettwer, U. Ravens, S.-P. Olesen, and M. Grunnet Biophysical Characterization of the New Human Ether-A-Go-Go-Related Gene Channel Opener NS3623 [N-(4-Bromo-2-(1H-tetrazol-5-yl)-phenyl)-N'-(3'-trifluoromethylphenyl)urea] Mol. Pharmacol., October 1, 2006; 70(4): 1319 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Casis, S.-P. Olesen, and M. C. Sanguinetti Mechanism of Action of a Novel Human ether-a-go-go-Related Gene Channel Activator Mol. Pharmacol., February 1, 2006; 69(2): 658 - 665. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
